<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of recurrent and resistant dermatomyositis and polymyositis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of recurrent and resistant dermatomyositis and polymyositis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of recurrent and resistant dermatomyositis and polymyositis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ira N Targoff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dermatomyositis (DM) and polymyositis (PM) are two classic forms of inflammatory myopathy. Most patients respond to initial therapy, and some achieve sustained disease control either off all therapy or with low-dose maintenance therapy. There are two additional patterns of response:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent disease – After achieving disease control with treatment, some patients experience disease recurrences (flares) during or after the period of medication tapering.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistant disease – In other patients, the disease does not respond entirely to conventional initial approaches to remission induction, and other therapies must be considered after excluding alternative diagnoses.</p><p></p><p>Approaches to the treatment of recurrent and resistant disease in adults with DM and PM will be reviewed here. The initial therapy of and clinical manifestations of these disorders in adults, the management of the cutaneous manifestations of dermatomyositis, and issues related to DM and PM in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/d/html/13771.html" rel="external">"Cutaneous dermatomyositis in adults: Overview and initial management"</a> and  <a class="medical medical_review" href="/d/html/6419.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/13774.html" rel="external">"Management of refractory cutaneous dermatomyositis in adults"</a> and  <a class="medical medical_review" href="/d/html/6418.html" rel="external">"Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RECURRENT DISEASE</span><span class="headingEndMark"> — </span>Complete discontinuation of treatment is unsuccessful in the majority of patients. For patients who experience disease flares after the achievement of disease control, a variety of clinical scenarios may occur. The following discussion, based primarily on the authors' experience, assumes that <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is tapered before attempts to discontinue either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>Flare at more than 10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> – Disease flares at such doses of prednisone require one of two actions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Addition of a glucocorticoid-sparing drug if neither <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> nor <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> has been used</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of the flare as a case of resistant disease if the patient is already taking either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (see <a class="local">'Resistant disease'</a> below)</p><p></p><p>With either action, a higher dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, generally in the range of 1 mg/kg per day, will be required to reestablish disease control.</p><p class="bulletIndent1"><span class="glyph">●</span>Flare at 10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or less – If a disease flare occurs at a prednisone dose of 10 mg/day or less, there are two options that are not mutually exclusive:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase in <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to the lowest dose required to reestablish disease control. This dose is based upon the severity of the patient's clinical findings. If the disease flare is detected early, the dose required may be significantly lower than 1 mg/kg per day. The usual minimum dose is 20 mg/day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase in <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> to a higher dose, if the dose of the patient's glucocorticoid-sparing drug has not already been maximized.</p><p></p><p>Once disease control is restored, we suggest slower tapering than that which was used during the initial course. Some patients are maintained on low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (eg, 5 mg/day) for one year or more.</p><p class="bulletIndent1"><span class="glyph">●</span>Flare off <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> but on a glucocorticoid-sparing drug – There are two options in such patients that are not mutually exclusive:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> is reinstituted at the lowest dose required to reestablish disease control. The dose selected is based upon the severity of the patient's clinical findings and may be significantly lower than 1 mg/kg if the disease flare is detected early. The usual minimum dose is 20 mg/day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The glucocorticoid-sparing drug can be changed from <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or vice versa.</p><p></p><p>If the patient has been treated previously with both <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, the flare should be regarded as a manifestation of resistant disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Flare off all immunosuppressive medications – <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> should be reinstituted with the daily dose varying with the severity of the relapse. The minimum starting dose of prednisone is 20 mg/day. In addition, a glucocorticoid-sparing drug should be resumed or started.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RESISTANT DISEASE</span><span class="headingEndMark"> — </span>Before initiating alternative therapies in patients with resistant disease, consideration should be given to an alternative diagnosis, particularly inclusion body myositis (IBM). The picture of weakness and atrophy of the quadriceps in addition to wrist and finger flexion involvement raises the suspicion of IBM (see  <a class="medical medical_review" href="/d/html/5163.html" rel="external">"Clinical manifestations and diagnosis of inclusion body myositis"</a>). A repeat biopsy may be necessary to confirm the diagnosis [<a href="#rid1">1</a>]. In addition, the initial response to glucocorticoids in the patient with dermatomyositis (DM) and polymyositis (PM) typically takes four to six weeks for normalization of creatine kinase (CK) levels, or three to four months to regain muscle strength; thus, a patient should not be classified as having resistant disease without considering these time factors.</p><p>Multiple options exist for treating patients who do not respond adequately to glucocorticoids plus <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. Evidence of clinically significant benefit is greatest with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG). We suggest using rituximab first in this setting, and then trying IVIG if rituximab fails. Additional considerations that may influence the choice of therapies include the presence of interstitial lung disease (ILD), particularly if it has not responded to initial treatment measures. (See  <a class="medical medical_review" href="/d/html/4357.html" rel="external">"Interstitial lung disease in dermatomyositis and polymyositis: Treatment"</a>.)</p><p>The reasons for favoring <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> over <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> has been associated with substantial improvement in DM and PM in patients with previously refractory disease. (See <a class="local">'Rituximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> appears to be effective in connective tissue disorders resembling DM and PM, such as systemic lupus erythematosus and rheumatoid arthritis (RA). (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If effective, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> may be more likely to lead to a prolonged period of disease control. Many patients who respond to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> require continued treatments on a monthly basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is less costly than <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>.</p><p></p><p>Other agents that may be of benefit include <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil; calcineurin inhibitors, such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>; and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. The choice of these other agents is often guided by comorbidities, insurance coverage, and cost, as comparative studies have not been performed.</p><p class="headingAnchor" id="H4"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> targets CD20-positive cells (ie, B-cell precursors), leading in most patients to the depletion of B cells in the blood within several weeks of administration. It is a promising agent for the treatment of both DM and PM. A variety of dosing regimens have been employed in a randomized trial and several small case series or case reports in patients with DM and PM [<a href="#rid2">2-9</a>]. In rheumatic disease (particularly RA), the trend with the use of rituximab is to employ two 1 gram doses two weeks apart.</p><p>Some data indicate that patients who suffer disease flares can be retreated effectively with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, but a larger clinical experience with this agent and additional randomized trials are required before definitive conclusions can be drawn. Observations with rituximab include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest trial of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in inflammatory myositis, the Rituximab in Myositis (RIM) trial, involved 195 patients, all of whom were treated with rituximab either at baseline or after an eight-week delay, including 76 patients with adult DM and PM and 48 patients with juvenile DM; all patients had disease refractory to glucocorticoids and at least one immunosuppressive or immunomodulatory agent (mean of 3.1 agents in addition to the glucocorticoid) [<a href="#rid2">2</a>]. The findings suggested that rituximab is potentially effective in these populations, but no differences in response to rituximab were seen between the two groups to which the patients were allocated.</p><p></p><p class="bulletIndent1">Patients were randomly assigned to receive <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (750 mg/m<sup>2</sup> up to 1 gram, administered intravenously once weekly for two weeks) either on weeks zero and one ("early arm") or on weeks eight and nine ("late arm"), and were assigned to receive placebo at the time point during which they did not receive rituximab. There were no differences between the early and late treatment arms in the time from baseline to achieve the composite response criteria (both at about 20 weeks) or 20 percent improvement in strength, nor were there differences between the two arms in the frequency with which the response criteria or 20 percent improvement in strength were achieved or in the rate of glucocorticoid taper. The disease groups (DM, PM, and juvenile DM) did not differ in outcome.</p><p></p><p class="bulletIndent1">Despite the failure to demonstrate differences based upon the eight-week treatment delay, the composite response criterion was achieved by 83 percent of the patients receiving <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> during the 44-week trial, and the mean dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in the 160 patients on it at baseline was significantly reduced, from 20.8 to 14.4 mg daily. Response criteria were also met after a second course of therapy by eight of nine patients eligible for retreatment after an initial response and later recurrence.</p><p></p><p class="bulletIndent1">Only one patient withdrew due to an adverse effect, although 26 serious adverse effects attributed to the <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> were observed, most of which were infections. These included pneumonia and cellulitis (six patients each), as well as urosepsis and herpes zoster (two patients each), and one patient each had septic arthritis, histoplasmosis, urinary tract infection, respiratory failure, heart failure, dysrhythmia, venous thrombosis, syncope, rash, and neurologic symptoms. One patient died during the trial from a suspected malignancy and stroke. Infusion reactions were more common with the administration of rituximab compared with placebo (15.4 versus 5.3 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other smaller case series have also demonstrated benefit, some with longer follow-up than the RIM trial or with different treatment regimens [<a href="#rid3">3-9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, 13 patients with refractory inflammatory myopathies were treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1 gram every other week for two treatments) and were followed for a mean of 27 months, showing a significant decrease in CK and improvement in strength by handheld dynamometry by 22 percent at 24 months [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study, six patients with DM were treated with 375 mg/m<sup>2</sup> once weekly times four doses [<a href="#rid3">3</a>]. All showed major clinical improvement, with the gain over baseline strength being evident as early as four weeks after the initial infusion and ranging from 36 to 113 percent. Additionally, extramuscular signs of disease, including rash, alopecia, and reductions in forced vital capacity, improved within 12 weeks. Disease flares during the one-year follow-up were seen in four patients, all between 24 and 36 weeks after treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several reports included patients with antisynthetase antibodies which remained elevated during therapy, despite good clinical responses to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid3">3,4</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Intravenous immune globulin</span><span class="headingEndMark"> — </span>For DM, immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) is a reasonable second-line therapy for patients with refractory disease. IVIG has received US Food and Drug Administration (FDA) approval for the treatment of adults with DM. Some physicians may use IVIG as a first-line therapy, particularly for patients at high risk of poor outcomes (eg, severe weakness, dysphagia). The expense of this treatment is an important consideration in its long-term use. (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p>The beneficial effects of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> for the treatment of DM have been supported by observational data and randomized trials [<a href="#rid10">10-15</a>]. The data supporting its use for the treatment of patients with PM are more limited [<a href="#rid15">15,16</a>]. In the largest randomized trial of 95 patients with DM, more patients achieved a response of at least minimal improvement based on a composite score of disease activity if they received IVIG compared with placebo (79 versus 44 percent) at 16 weeks [<a href="#rid10">10</a>]. At enrollment, patients were allowed to be on a maximum of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg daily (or equivalent) as well as a maximum of two immunosuppressive drugs. When the outcome was defined as either a moderate or major improvement on the composite disease activity score, more patients in the IVIG group continued to have more favorable results. The trial was extended open-label to a total of 40 weeks, in which all participants received treatment with IVIG. The open-label phase was associated with a corresponding increase in treatment-related adverse events, including thromboembolic events.</p><p>The rate of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> infusion may influence the risk of thromboembolism in patients with DM. In this study, reduction of the maximum infusion rate from 0.12 mL/kg/minute to 0.04 mL/kg/minute led to a corresponding decline in thromboembolic events (1.54 per 100 patient-months versus 0.54 per 100 patient-months) [<a href="#rid10">10</a>]. Larger and longer-term trials are needed to further clarify the efficacy and safety of IVIG for the treatment of DM.</p><p>An alternative subcutaneous approach to the administration of immunoglobulin in patients with DM and PM has also been associated with clinical improvement in strength and quality of life measures [<a href="#rid17">17</a>]. In this small case series of seven patients, the usual monthly dose was divided into weekly doses given subcutaneously through a programmable pump, and the treatment appeared to be safe and well-tolerated.</p><p class="headingAnchor" id="H3169810404"><span class="h2">Mycophenolate mofetil</span><span class="headingEndMark"> — </span>We suggest using <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil as a second-line agent in patients who have failed to respond to either <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, or in patients with interstitial lung disease (ILD; for whom methotrexate may be contraindicated). Mycophenolate mofetil is less expensive and easier to administer than other agents used to treat patients with resistant disease (ie, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>). Trials comparing the relative efficacy of these agents for the treatment of refractory myositis are not available.</p><p><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil has been used with some success in retrospective series of patients with inflammatory myopathy [<a href="#rid18">18-21</a>]. These case series suggest a role for mycophenolate mofetil in the treatment of resistant myositis. The use of mycophenolate mofetil in patients with DM/PM-associated ILD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4357.html" rel="external">"Interstitial lung disease in dermatomyositis and polymyositis: Treatment", section on 'Mycophenolate mofetil'</a>.)</p><p>The following observations illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective series included 10 DM patients with a history of refractory disease [<a href="#rid19">19</a>]. After initiation of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, manual muscle testing scores improved in five, and the glucocorticoid dose could be tapered in six. Serious opportunistic infections occurred in 3 of the 10 patients: a <em>Mycobacterium xenopi</em> abscess of the thigh; pulmonary blastomycosis; and <em>Legionella</em> pneumonia (fatal). However, it is likely that the patients' immunosuppressive regimens prior to the use of mycophenolate mofetil contributed to the development of opportunistic infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second report, six patients with treatment-resistant myositis (two with DM, three with PM, one with overlap myositis) were treated for a mean of 22 months with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (mean dose 1.6 g/day) [<a href="#rid20">20</a>]. Both muscle strength and serum CK levels improved in all patients, and the mean <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose was tapered from 13.7 to 8.5 mg/day.</p><p></p><p>Clinicians prescribing <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil for inflammatory myopathy must be alert to the possibility of opportunistic infection.</p><p class="headingAnchor" id="H7"><span class="h2">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>The calcineurin inhibitors, which include <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, achieve their effects by interfering with T cell function. Data on the use of calcineurin inhibitors in DM and PM are limited to retrospective case series and to anecdotal reports; however, both appear to have some role in the treatment of resistant DM and PM. The limited evidence available suggests that tacrolimus offers some advantage over cyclosporine in efficacy, but larger studies are required before definitive conclusions are possible.</p><p class="headingAnchor" id="H8"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span>Efficacy for <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> has been suggested for both primary therapy [<a href="#rid22">22,23</a>] and resistant disease, including ILD [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/d/html/4304.html" rel="external">"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis"</a>.)</p><p>In one report, six patients previously resistant to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and/or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> underwent treatment with a mean daily <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> dose of 3.5 mg/kg [<a href="#rid24">24</a>]. Over the median six-month course of treatment with cyclosporine, the mean daily <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose was reduced by 75 percent. All six patients demonstrated improved strength in the shoulder girdle; four had stronger hip flexor muscles.</p><p class="headingAnchor" id="H9"><span class="h3">Tacrolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> has been used in a limited number of patients with inflammatory myopathy. The optimal dose for this indication is not certain.</p><p>It has been suggested that <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> may be particularly effective in cases of inflammatory myopathy complicated by ILD. In one report, tacrolimus (0.075 mg/kg per day in two divided doses) was effective in a series of eight patients with refractory PM [<a href="#rid26">26</a>]. Strength normalized in five of six anti-Jo-1 antibody-positive patients and improved in the two anti-signal recognition particle (SRP) positive patients. The mean CK declined from 3114 to 87 international units/mL. Three of five patients with ILD also showed improvement in pulmonary function.</p><p>In a second series from the same authors with minor overlap, 13 patients with the antisynthetase syndrome and ILD were treated with <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for a mean duration of 51 months [<a href="#rid27">27</a>]. Twelve of the patients had antibodies to Jo-1 and one had antibodies to PL-12. The following benefits were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum CK levels improved by 75 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>Manual testing of muscle strength improved or remained stable in 10 of 13 patients.</p><p class="bulletIndent1"><span class="glyph">●</span>The mean <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose was tapered by 67 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>There were substantial improvements in forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the diffusing capacity for carbon monoxide (DLCO).</p><p></p><p>In other small series of patients with ILD, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> appeared to be beneficial in patients who were not controlled with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Cyclophosphamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> (which is infrequently used because of greater toxicity than cyclophosphamide) may be effective in treating myositis [<a href="#rid30">30,31</a>], but their utility is limited by their potential for toxicity, particularly the induction of malignancy. A more detailed discussion of dosing, dose adjustments, and adverse effects is presented separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p>One study evaluated the use of intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) for progressive ILD in 17 patients with DM or PM [<a href="#rid32">32</a>]. The patients were treated with intravenous cyclophosphamide at doses ranging from 300 to 800 mg/m<sup>2</sup> every four weeks. All patients received at least six courses.</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Eleven of the 17 patients showed improvement in their dyspnea.</p><p class="bulletIndent1"><span class="glyph">●</span>Six of the seven patients who required supplemental oxygen were able to discontinue supplemental oxygen use.</p><p class="bulletIndent1"><span class="glyph">●</span>Twelve of the patients had improvements in FVC of at least 10 percent. For the group overall, the mean FVC improved by 15 percent over baseline, from 68 to 83 percent predicted.</p><p></p><p>In the absence of aggressive ILD or systemic vasculitis, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be considered only in patients who fail to respond to multiple other second-line agents.</p><p>Given the efficacy of alkylating agents in the treatment of vasculitides, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> may also be useful in patients with inflammatory myopathy who develop the complication of systemic vasculitis. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p class="headingAnchor" id="H440961900"><span class="h2">Corticotropin injection gel</span><span class="headingEndMark"> — </span>A case series has suggested that <a class="drug drug_general" data-topicid="8885" href="/d/drug information/8885.html" rel="external">corticotropin injection gel</a>, a form of adrenocorticotropic hormone, may be beneficial in patients with exacerbations of DM or PM despite ongoing therapy with other immunosuppressive agents [<a href="#rid33">33</a>]. However, in the absence of proven benefit and the high cost of this drug, we do not recommend the use of corticotropin injection gel for resistant DM or PM.</p><p class="headingAnchor" id="H14"><span class="h2">Combination methotrexate and azathioprine</span><span class="headingEndMark"> — </span>Combination therapy may be effective among those with resistant disease. This combination might be considered in the patient for whom <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or other options were unaffordable or ineffective. The only published study regarding combination treatment is a crossover study in which 30 patients with refractory myositis were randomly assigned to either a combination of weekly oral <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and daily <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or to intravenous methotrexate with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> rescue every two weeks for six months [<a href="#rid34">34</a>]. The doses used in the study were methotrexate 7.5 mg per week and azathioprine 50 mg/day to start, with escalation to a maximum dose of 25 mg and 150 mg/day. Twenty-five of the patients had had inadequate responses to previous cytotoxic therapies.</p><p>The results were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Among the 15 patients initially assigned to oral <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>/<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, eight improved with oral therapy, and one improved with intravenous methotrexate during the crossover period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of the 15 patients initially assigned to intravenous <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> therapy, three improved with intravenous therapy and four with oral combination therapy during the crossover period.</p><p></p><p>This study did not have sufficient power to compare the two treatment regimens. However, the data indicate that either the combination of oral <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or high dose intravenous methotrexate with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> rescue may benefit some patients with refractory disease.</p><p class="headingAnchor" id="H340241544"><span class="h2">Janus kinase inhibitors</span><span class="headingEndMark"> — </span>There are case reports and small series suggesting that Janus kinase (JAK) inhibitors may be effective in DM. This effect may be mediated by preventing the observed upregulation of type 1 interferon [<a href="#rid35">35</a>].</p><p>A case report suggested that <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>, a JAK inhibitor developed to treat neoplastic diseases, may be effective for treating resistant DM [<a href="#rid36">36</a>]. The report describes a 72-year-old woman with severe DM that was only partially responsive to several different treatment regimens, including glucocorticoids, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil. Approximately one year later, she was diagnosed with a JAK2 mutation-associated myeloproliferative neoplasm for which she was given ruxolitinib. Her DM symptoms rapidly improved, and by 12 months her DM was in remission on monotherapy with ruxolitinib. Although the immunomodulatory effects of ruxolitinib in the treatment of DM appear to be promising, more data are needed to establish efficacy for this indication. The possibility that her DM may be paraneoplastic, and therefore that the treatment of the underlying disease was the cause for improvement, cannot be excluded. (See  <a class="medical medical_review" href="/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis"</a>.)</p><p>In two small series of patients with multidrug-resistant cutaneous DM, the rash responded to <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid37">37,38</a>]. In another report, two patients with rapidly progressive calcinosis cutis responded to tofacitinib, and in one of these patients, severe ILD also responded to tofacitinib [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H211474770"><span class="h1">EXTRAMUSCULAR DISEASE</span></p><p class="headingAnchor" id="H211473126"><span class="h2">Interstitial lung disease</span><span class="headingEndMark"> — </span>The presence of interstitial lung disease (ILD) may influence the choice of therapeutic agents. The treatment of ILD resistant to initial therapies is described in detail separately. (See  <a class="medical medical_review" href="/d/html/4357.html" rel="external">"Interstitial lung disease in dermatomyositis and polymyositis: Treatment"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Refractory rash</span><span class="headingEndMark"> — </span>In some cases of dermatomyositis (DM), the cutaneous manifestations are more refractory to treatment than the muscle disease. A variety of approaches to the problem of refractory cutaneous DM have been taken. The management of the cutaneous manifestations of DM, including initial management and the treatment of manifestations that are resistant to initial therapy, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/13771.html" rel="external">"Cutaneous dermatomyositis in adults: Overview and initial management"</a> and  <a class="medical medical_review" href="/d/html/13774.html" rel="external">"Management of refractory cutaneous dermatomyositis in adults"</a>.)</p><p class="headingAnchor" id="H3651767446"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114586.html" rel="external">"Society guideline links: Dermatomyositis and polymyositis"</a>.)</p><p class="headingAnchor" id="H15109376"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82977.html" rel="external">"Patient education: Dermatomyositis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83085.html" rel="external">"Patient education: Polymyositis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p>Many patients with dermatomyositis (DM) or polymyositis (PM) require intermittent or even continuous therapy (see <a class="local">'Recurrent disease'</a> above and <a class="local">'Resistant disease'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent disease is defined as the occurrence of a disease flare following the achievement of disease control with treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistant disease does not respond sufficiently to the conventional approaches of glucocorticoids plus either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. In such cases, other therapies must be considered after excluding alternative diagnoses.</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Recurrent disease</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who experience disease flares after the achievement of disease control, there are several specific scenarios (see <a class="local">'Recurrent disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For disease flares at more than 10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, we suggest the addition of either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (if not already used) or treatment of the patient as a case of resistant disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For disease flares at 10 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or less, we suggest increasing the prednisone to the lowest dose required to reestablish disease control and/or increasing the <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> dose, if this has not been maximized already (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For disease flares off <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> but on a glucocorticoid-sparing drug, we suggest reinstituting prednisone at the lowest dose required to reestablish disease control and/or changing the glucocorticoid-sparing medication from <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or vice versa (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">If the patient has already failed both <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, treatment as a case of resistant disease is appropriate. (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For flares off all immunosuppressive medication, we suggest reinstituting <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> with an initial daily dose that varies according to relapse severity (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The minimum starting dose of prednisone is 20 mg/day. In addition, a glucocorticoid-sparing drug should be resumed or started.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Resistant disease</span></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple options exist for treating patients who do not respond adequately to glucocorticoids plus either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. Options for the treatment of resistant disease include (see <a class="local">'Resistant disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a></p><p class="bulletIndent2"><span class="glyph">•</span>Combination therapy with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest using <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (two 1 gram doses two weeks apart) in the treatment of resistant disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Rituximab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is not effective, we suggest <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> as the second-line agent for the treatment of resistant DM (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Intravenous immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of interstitial lung disease (ILD) may influence treatment choices. (See <a class="local">'Interstitial lung disease'</a> above and  <a class="medical medical_review" href="/d/html/4357.html" rel="external">"Interstitial lung disease in dermatomyositis and polymyositis: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with inflammatory myopathy, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (1 to 1.5 g twice daily) is a reasonable alternative if <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> have failed. (See <a class="local">'Mycophenolate mofetil'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of their substantial side effect profiles, we suggest reserving alkylating agents (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>) for patients whose disease has proven resistant to multiple other treatment options (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination therapy with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (up to 200 mg/day) and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (up to 25 mg/week) hold some potential for efficacy in patients with resistant disease. However, the risk of treatment-related morbidity when using both of these medications together mandates the utmost care in monitoring patients for cytopenias and other adverse effects. (See <a class="local">'Combination methotrexate and azathioprine'</a> above.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Refractory rash</span></p><p class="bulletIndent1"><span class="glyph">●</span>In some cases of DM, the cutaneous findings are more refractory to treatment than is the muscle disease, and additional management approaches are required. (See <a class="local">'Refractory rash'</a> above and  <a class="medical medical_review" href="/d/html/13771.html" rel="external">"Cutaneous dermatomyositis in adults: Overview and initial management"</a> and  <a class="medical medical_review" href="/d/html/13774.html" rel="external">"Management of refractory cutaneous dermatomyositis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3646303852"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stacy Rudnicki, MD and Marc L Miller, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176.</a></li><li><a class="nounderline abstract_t">Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314.</a></li><li><a class="nounderline abstract_t">Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.</a></li><li><a class="nounderline abstract_t">Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65:974.</a></li><li><a class="nounderline abstract_t">Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33:1021.</a></li><li><a class="nounderline abstract_t">Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32:1369.</a></li><li><a class="nounderline abstract_t">Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50:2206.</a></li><li><a class="nounderline abstract_t">Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27:1009.</a></li><li><a class="nounderline abstract_t">Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022; 387:1264.</a></li><li><a class="nounderline abstract_t">Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993.</a></li><li><a class="nounderline abstract_t">Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012; 22:382.</a></li><li><a class="nounderline abstract_t">Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91:162.</a></li><li><a class="nounderline abstract_t">Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009; 9:124.</a></li><li><a class="nounderline abstract_t">Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2008; 18:34.</a></li><li><a class="nounderline abstract_t">Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46:467.</a></li><li><a class="nounderline abstract_t">Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011; 10:144.</a></li><li><a class="nounderline abstract_t">Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002; 25:286.</a></li><li><a class="nounderline abstract_t">Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66:1245.</a></li><li><a class="nounderline abstract_t">Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007; 46:516.</a></li><li><a class="nounderline abstract_t">Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44:386.</a></li><li><a class="nounderline abstract_t">Grau JM, Herrero C, Casademont J, et al. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994; 21:381.</a></li><li><a class="nounderline abstract_t">Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29:95.</a></li><li><a class="nounderline abstract_t">Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.</a></li><li><a class="nounderline abstract_t">Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997; 26:24.</a></li><li><a class="nounderline abstract_t">Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762.</a></li><li><a class="nounderline abstract_t">Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439.</a></li><li><a class="nounderline abstract_t">Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38:383.</a></li><li><a class="nounderline abstract_t">Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23:707.</a></li><li><a class="nounderline abstract_t">Bombardieri S, Hughes GR, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; 1:1138.</a></li><li><a class="nounderline abstract_t">Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36:319.</a></li><li><a class="nounderline abstract_t">Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46:124.</a></li><li><a class="nounderline abstract_t">Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012; 6:133.</a></li><li><a class="nounderline abstract_t">Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41:392.</a></li><li><a class="nounderline abstract_t">Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 2018; 141:1609.</a></li><li><a class="nounderline abstract_t">Hornung T, Janzen V, Heidgen FJ, et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 2014; 371:2537.</a></li><li><a class="nounderline abstract_t">Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol 2016; 152:944.</a></li><li><a class="nounderline abstract_t">Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford) 2019; 58:1011.</a></li><li><a class="nounderline abstract_t">Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases. J Autoimmun 2019; 100:131.</a></li></ol></div><div id="topicVersionRevision">Topic 5133 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994327" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term observational study of sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124935" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692974" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Rituximab in the treatment of dermatomyositis: an open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769789" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rituximab in the treatment of antisynthetase syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16541475" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rituximab as therapy for refractory polymyositis and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996082" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy of rituximab in refractory polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21571768" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rituximab treatment in patients with refractory inflammatory myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20149324" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20506493" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198179" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trial of Intravenous Immune Globulin in Dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8247075" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21971943" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1714235" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386287" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217197" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11840450" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858553" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870700" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636243" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mycophenolate mofetil in dermatomyositis: is it safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003173" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycophenolate mofetil treatment in resistant myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572389" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182665" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cyclosporine A as first choice therapy for dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777122" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11128676" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057798" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347992" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tacrolimus in refractory polymyositis with interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052580" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227154" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173253" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2566079" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cyclophosphamide in severe polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452575" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22787386" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506565" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29741608" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25539124" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Remission of recalcitrant dermatomyositis treated with ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27120749" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30608616" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30862449" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
